No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BBIO BridgeBio Pharma
- 27.860
- -1.140-3.93%
Close Jun 14 16:00 ET
- 27.870
- +0.010+0.04%
Post 19:00 ET
5.21BMarket Cap-8625P/E (TTM)
28.550High27.470Low1.13MVolume28.430Open29.000Pre Close31.54MTurnover0.93%Turnover RatioLossP/E (Static)187.13MShares44.32052wk High-4.97P/B3.38BFloat Cap14.77652wk Low--Dividend TTM121.21MShs Float73.500Historical High--Div YieldTTM3.72%Amplitude4.980Historical Low27.858Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
J.P. Morgan analyst Anupam Rama maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 45.5% and a
Citi Opens Upside Catalyst Watch on Alnylam Ahead of ATTR-CM Data
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases an
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases an
BridgeBio Pharma(BBIO.US) Director Sells US$75,792.52 in Common Stock
$BridgeBio Pharma(BBIO.US)$ Director Scott Randal W. sold 2,500 shares of common stock on Jun 3, 4, 2024 at an average price of $30.317 for a total value of $75,792.52.Source: Announcement What is sta
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)--$BBIO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio"
Comments
Morning Movers
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
17
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index(.SPX.US$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
28
1
$BridgeBio Pharma(BBIO.US$ BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg